doi: 10.1056/NEJMp048286.
Epub 2004 Oct 6.
Failing the public health--rofecoxib, Merck, and the FDA
Affiliations
- PMID: 15470193
- DOI: 10.1056/NEJMp048286
Item in Clipboard
Failing the public health--rofecoxib, Merck, and the FDA
N Engl J Med.
.
Free article
No abstract available
Comment in
-
Rofecoxib, Merck, and the FDA.N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8. doi: 10.1056/NEJM200412303512719. N Engl J Med. 2004. PMID: 15625342 No abstract available.
-
Rofecoxib, Merck, and the FDA.N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8. N Engl J Med. 2004. PMID: 15625745 No abstract available.
-
Rofecoxib, Merck, and the FDA.N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8. N Engl J Med. 2004. PMID: 15625749 No abstract available.
Similar articles
-
Rofecoxib, Merck, and the FDA.N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8. doi: 10.1056/NEJM200412303512719. N Engl J Med. 2004. PMID: 15625342 No abstract available.
-
Rofecoxib, Merck, and the FDA.N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8. N Engl J Med. 2004. PMID: 15625745 No abstract available.
-
Rofecoxib, Merck, and the FDA.N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8. N Engl J Med. 2004. PMID: 15625749 No abstract available.
-
Pharmacometrics at FDA: evolution and impact on decisions.Clin Pharmacol Ther. 2007 Jul;82(1):97-102. doi: 10.1038/sj.clpt.6100234. Epub 2007 May 30. Clin Pharmacol Ther. 2007. PMID: 17538553 Review.
-
Unapproved drugs in the United States and the Food and Drug Administration.Adv Ther. 2011 Oct;28(10):842-56. doi: 10.1007/s12325-011-0059-4. Epub 2011 Sep 1. Adv Ther. 2011. PMID: 21894470 Review.
Cited by
-
NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead.RSC Adv. 2024 Sep 25;14(42):30647-30661. doi: 10.1039/d4ra04686b. eCollection 2024 Sep 24. RSC Adv. 2024. PMID: 39324041 Free PMC article. Review.
-
Repurposing Drugs for Cancer Prevention: Targeting Mechanisms Common to Chronic Diseases.Cancer J. 2024 Sep-Oct 01;30(5):345-351. doi: 10.1097/PPO.0000000000000746. Cancer J. 2024. PMID: 39312454 Review.
-
Present and Future of Pharmacological Management for Acute Moderate-to-Severe Postoperative, Traumatic, or Musculoskeletal Pain in Europe: A Narrative Review.Pain Ther. 2024 Dec;13(6):1351-1376. doi: 10.1007/s40122-024-00645-y. Epub 2024 Sep 21. Pain Ther. 2024. PMID: 39305453 Free PMC article. Review.
-
Single dose thermoresponsive dexamethasone prodrug completely mitigates joint pain for 15 weeks in a murine model of osteoarthritis.Nanomedicine. 2024 Apr;57:102735. doi: 10.1016/j.nano.2024.102735. Epub 2024 Jan 29. Nanomedicine. 2024. PMID: 38295913
-
The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review.Pain Ther. 2023 Jun;12(3):655-669. doi: 10.1007/s40122-023-00501-5. Epub 2023 Apr 24. Pain Ther. 2023. PMID: 37093356 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
